TG Therapeutics, Inc. (TGTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Morrisville, NY, United States. El CEO actual es Michael S. Weiss.
TGTX tiene fecha de IPO 2010-05-03, 352 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $5.53B.
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel treatments targeting B-cell malignancies and autoimmune diseases. The company's lead products include Ublituximab, a monoclonal antibody for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple sclerosis, and Umbralisib, an oral PI3K-delta and CK1-epsilon inhibitor for various lymphomas and leukemia. The pipeline also includes clinical and preclinical candidates such as Cosibelimab (a PD-L1 inhibitor), TG-1701 (a BTK inhibitor), TG-1801 (a bispecific CD47/CD19 antibody), and programs targeting BET, IRAK-4, and GITR. Founded in 1993 and headquartered in New York, TG Therapeutics maintains strategic collaborations and partnerships with leading global pharmaceutical and biotechnology organizations to advance its therapeutic development programs.
